STOCK TITAN

Histogen to Report Second Quarter 2021 Financial Results on August 11, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Histogen’s financial results for the second quarter will be released after the close of market on Wednesday, August 11, 2021.

About Histogen Inc.

Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including joint cartilage regeneration, spinal disk repair, hair growth and dermal rejuvenation. For more information, please visit www.histogen.com.

CONTACT:

Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
ir@histogen.com


HISTOGEN INC

OTC:HSTO

HSTO Rankings

HSTO Latest News

HSTO Stock Data

2.14M
3.93M
2.85%
5.25%
1.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
San Diego

About HSTO

a regenerative medicine company based on naturally-produced products from newborn fibroblasts grown in a proprietary bioreactor. two product families - a proprietary liquid complex of embryonic-like proteins and growth factors, and a human extracellular matrix (ecm) material, exceltrix.